The UK’s MedTech Directorate is undergoing a partial relaunch, with a new director set to take the reins and a new strategy being finalized. The medtech industry hopes the renewed impetus will put long-overdue attention to value-based procurement for medtech goods.
The much-touted MedTech Directorate, a UK Department of Health and Social Care (DHSC) body with a broad remit to oversee medtech strategy, medtech delivery, continuity of supplies and supplier relationship management, is nearer to being put on an official and permanent footing.
Much still remains to be decided, including the finer points of the strategy for a body that was claimed by the government to be making good progress 18 months ago,...
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.
Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.
